McDermott Advises Aelis Farma on its IPO on Euronext Paris
McDermott Will & Emery advised Aelis Farma, a biopharmaceutical company specializing in the development of treatments for brain diseases, on its EUR 25 million initial public offering and listing on the regulated market Euronext Paris, which successfully closed on February 17, 2022.
This transaction was carried out by way of an open price offer in France and a global placement to institutional investors, including a private placement to QIBs in the United States. This was the largest IPO by market capitalization of a biotech on Euronext Paris in the past 5 years.
Aelis Farma is developing a new class of drugs that provide access to several therapeutic areas without available treatments. Aelis Farma has 2 products in clinical development, including AEF0117 for cannabis-related disorders, and AEF0217 for cognitive deficits, and is of the origin of a new class of drug, CB1-SSi, targeting the CB1 receptor of the endocannabinoid system. With the funds raised, Aelis Farma will be able to accelerate the development of its new generation of drugs, CB1-SSi.
The McDermott team that advised Aelis Farma comprised:
David Revcolevschi, Partner, Mathilde Peschard, Associate, Théa Delhaye and Ludivine Rabreau, Associates (capital markets and corporate) and Joe Marx, Partner (US securities law) ;
Emmanuelle Trombe, Partner (Healthcare) ;
Charles de Raignac and Edouard Becker (IP), Associates ; and
Côme de Saint-Vincent, Counsel (Tax).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.